

# Novel Coronavirus Disease (COVID-19)

## Situation Update Report – 92

November 3, 2021

### HIGHLIGHTS

- Prime Minister holds review meeting with districts having low vaccination coverage ([Link](#))
- Center rushes High Level teams to 9 States/UTs with high caseload of Dengue in accordance with directions of Union Health Minister ([Link](#))
- Union Health Minister reviews Dengue situation in Delhi ([Link](#))
- Union Health Minister launches nationwide expansion of Pneumococcal Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP) ([Link](#))

### INDIA SITUATION

- As of 2 November 2021, India reported a total of 34,296,237 confirmed cases. In the past 24 hours, 10,423 confirmed cases have been reported, which is the lowest single day cases after second wave. Top five states, namely, Maharashtra, Kerala, Karnataka, Tamil Nadu, and Andhra Pradesh are contributing 56% of total cases

#### WHO Situation Update

India

**34,296,237 Confirmed Cases**

**458,880 Total Deaths**

South East Asia Region

**44,005,474 Confirmed Cases**

**693,814 Total Deaths**

World

**246,951,274 Confirmed Cases**


**5,004,855 Deaths**

In comparison to previous week (20-26 October), less than 30% of districts have shown an increase in new cases during last week (27 October – 2 November). Additionally, amongst the top ten districts reporting highest number of cases during last week only one have shown increase in number of cases

District	Last 7 days Cases	Last 8-14 days Cases	% increase/decrease
ERNAKULAM	7,346	9,697	-24
THIRUVANANTHAPURAM	6,897	8,319	-17
THRISSUR	5,728	6,643	-14
KOZHIKODE	5,464	5,364	2
KOLLAM	4,434	4,786	-7
KOTTAYAM	4,075	4,712	-14
PATHANAMTHITTA	2,911	3,168	-8
IDUKKI	2,682	3,467	-23
KANNUR	2,626	3,155	-17
MALAPPURAM	2,540	3,287	-23

### COVID-19: STATUS ACROSS STATES

- In the last week (27 October -2 November), as compared to previous week (20 October- 26 October), 16 States/UTs have recorded rise in number new cases and 10 States/UTs have reported increase in number of deaths.



# Novel Coronavirus Disease (COVID-19) Situation Update Report – 92

November 3, 2021

## WHO GLOBAL UPDATE

- COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) has issued updated statement regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines, details [here](#)
- New ACT-Accelerator strategy calls for US\$ 23.4 billion international investment to solve inequities in global access to COVID-19 vaccines, tests & treatments. The Accelerator has launched its strategic plan and budget for the next 12 months, outlining the urgent actions and funding needed to address inequities, details [here](#)
- WHO, International Organization for Migration and UN High Commissioner for Refugees writes an open letter to G20 Heads of State and Government to make vaccines accessible to people on the move, details [here](#)
- WHO calls on countries to build resilient and healthy cities. On World Cities Day 2021, WHO asserts that climate and COVID-19 crises have exacerbated existing social injustices and vulnerabilities in our communities and our health systems, especially in cities, details [here](#)

## WHO COUNTRY UPDATE

### Coordination

- WHO supported NCDC to adopt the WCO warning level dashboard in the IHIP/IDSP portal. This was made live this week and can be used by the states and district officials for closely monitoring the trends.
- WHO field staff continue to participate in meetings on current response, third wave preparations, vaccination; chaired by Chief Ministers, Health Ministers, Health Secretaries, MDs- NHM, etc
- Supported operational planning of special vaccination drive 'Mission Yuva Swasth' to target COVID19 vaccination of college students in **Maharashtra**.

### COVID-19 vaccination

- Technical oversight during vaccination is provided by WHO teams at district and state levels.
- WCO is supporting monitoring of vaccination sessions across the country and continues to provide surge support for training, microplanning and monitoring.

### Surveillance, Contact Tracing and Containment

- WHO Country office provided technical support and supportive supervision to monitor contact tracing; identify containment zones for COVID-19 containment activities in **Uttar Pradesh** and provided feedback to the government health officials.
- Assisting a house to house survey for ILI/SARI in **Daman & Diu and Dadar & Nagar Haveli, and UP**

### Capacity building

- Supported the dissemination workshop of WHO Unity Study conducted by Department of Community Medicine, MAMC, **Delhi**.
- Participated in the national ToT on ZyCoV Pharma jet device in **Kerala**.
- A state level orientation of field staff on Pharmajet was supported for needleless COVID vaccination in **Rajasthan**

### Risk Communication and Community Engagement

- Promoted RCCE activities in **Chhattisgarh, Gujarat, and Madhya Pradesh** regarding COVID-19 in light of the upcoming festive and wedding season

### Support in ensuring delivery of Essential Health Services

- Strengthening VPD surveillance and immunization are underway in **Andhra Pradesh, Kerala, Karnataka, Lakshadweep, Puducherry, Telangana, Tamil Nadu, Madhya Pradesh, Maharashtra, and Jammu & Kashmir**
- Streamlining AEFI surveillance in **Delhi and Karnataka**
- Supporting Fever and rash surveillance in **Rajasthan**

# Novel Coronavirus Disease (COVID-19)

## Situation Update Report – 92


November 3, 2021

As of 2 November 2021, India has tested more than 593 million samples. Tests include both, RTPCR and Rapid Antigen. India's current test positivity rate (7DMA) is 1.17%.

### Testing - National Level


**59,30,20,838 \***

Cumulative Tests



India continued to drive COVID-19 vaccinations among various age group with preconditions, details [here](#).

Cumulative Coverage Report of COVID-19 vaccination (as on 2 November 2021, 07:00 AM)



## IMPORTANT GUIDELINES/TECHNICAL PUBLICATIONS

- Maintaining Essential Health Services during COVID-19 ([LINK](#))
- Responding to NCDs during and beyond the COVID-19 pandemic: examples of actions ([LINK](#))
- Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm ([LINK](#)), Annexes ([LINK](#))

Click to access latest publications from [WHO](#) and [MoHFW](#)

## FOR MORE INFORMATION CONTACT

In case of any queries on COVID-19, call +91-11-23978046 or 1075 (Toll-free). State Helpline [here](#).  
WHO Country Office for India | Telephone number: [+91-11-66564800](#) | Email: [wrindia@who.int](#)